Globus Medical (NYSE: GMED) and Cardiovascular Systems (NASDAQ:CSII) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.
Risk & Volatility
Globus Medical has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, Cardiovascular Systems has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500.
This is a summary of recent ratings and target prices for Globus Medical and Cardiovascular Systems, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Globus Medical presently has a consensus target price of $48.83, indicating a potential downside of 4.77%. Cardiovascular Systems has a consensus target price of $26.50, indicating a potential upside of 2.32%. Given Cardiovascular Systems’ higher possible upside, analysts plainly believe Cardiovascular Systems is more favorable than Globus Medical.
This table compares Globus Medical and Cardiovascular Systems’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Globus Medical and Cardiovascular Systems’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Globus Medical||$635.98 million||7.77||$107.34 million||$1.21||42.38|
|Cardiovascular Systems||$204.91 million||4.20||-$1.79 million||($0.10)||-259.00|
Globus Medical has higher revenue and earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
64.2% of Globus Medical shares are held by institutional investors. Comparatively, 80.9% of Cardiovascular Systems shares are held by institutional investors. 28.2% of Globus Medical shares are held by insiders. Comparatively, 3.3% of Cardiovascular Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Globus Medical beats Cardiovascular Systems on 11 of the 14 factors compared between the two stocks.
Globus Medical Company Profile
Globus Medical, Inc. (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies. The Company sells its products through exclusive sales force in the United States, as well as within North, Central & South America, Europe, Asia, Africa and Australia. The sales force consists of direct sales representatives and distributor sales representatives employed by exclusive independent distributors.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company’s coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.